Administration of CI-1033, an irreversible Pan-erbB tyrosine kinase inhibitor, is feasible on a 7-day on, 7-day off schedule: A phase I pharmacokinetic and food effect study

被引:63
作者
Calvo, E
Tolcher, AW
Hammond, LA
Patnaik, A
de Bono, JS
Eiseman, IA
Olson, SC
Lenehan, PF
McCreery, H
LoRusso, P
Rowinsky, EK
机构
[1] Univ Texas, Inst Drug Dev, Canc Therapy & Res Ctr, Hlth Sci Ctr, San Antonio, TX 78229 USA
[2] Ann Arbor Labs, Pfizer Global Res & Dev, Ann Arbor, MI USA
[3] Wayne State Univ, Ctr Hlth, Detroit, MI USA
关键词
D O I
10.1158/1078-0432.CCR-04-1187
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To determine the maximum tolerated dose of administrating CI-1033, an oral 4-anilinoquinazoline that irreversibly inhibits the tyrosine kinase domain of all erbB subfamilies, on an intermittent schedule, and assess the interaction of CI-1033 with food on the pharmaco fkinetic behavior. Experimental Design: Escalating doses of CI-1033 from a dose level of 300 mg/day for 7 days every other week were administered to patients with advanced solid malignancies. Plasma concentration-time data sets from all evaluable patients were used to develop a population pharmacokinetic model. Noncompartmental methods were used to independently assess the effect of a high-fat meal on CI-1033 absorption and bioavailability. Results: Twenty-four patients were treated with 69 twenty-eight day courses. The incidence of unacceptable toxicity, principally diarrhea and skin rash, was observed at the 300 mg/day dose level. At the 250 mg/day level, toxicity was manageable, and protracted administration was feasible. A one-compartment linear model with first-order absorption and elimination adequately described the pharmacokinetic disposition. CL/F, apparent volume of distribution (V-d/F), and k(a) (mean +/- relative SD) were 280 L/hour +/- 33%, 684 L +/- 20%, and 0.35 hour(-1) +/- 69%, respectively. C-max values were achieved in 2 to 4 hours. Systemic CI-1033 exposure was largely unaffected by administration of a high-fat meal. At 250 mg, concentration values exceeded IC50 values required for prolonged pan-erbB tyrosine kinase inhibition in preclinical assays. Conclusions: The recommended dose on this schedule is 250 mg/day. Its tolerability and the biological relevance of concentrations achieved at the maximal tolerated dose warrant consideration of disease-directed evaluations. This intermittent treatment schedule can be used without regard to meals.
引用
收藏
页码:7112 / 7120
页数:9
相关论文
共 45 条
  • [1] Cl-1033, an irreversible pan-erbB receptor inhibitor and its potential atmlication for the treatment of breast cancer
    Allen, LF
    Eiseman, IA
    Fry, DW
    Lenehan, PF
    [J]. SEMINARS IN ONCOLOGY, 2003, 30 (05) : 65 - 78
  • [2] Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer
    Allen, LF
    Lenehan, PF
    Eiseman, IA
    Elliott, WL
    Fry, DW
    [J]. SEMINARS IN ONCOLOGY, 2002, 29 (03) : 11 - 21
  • [3] Almadori G, 1999, INT J CANCER, V84, P188
  • [4] Unliganded epidermal growth factor receptor dimerization induced by direct interaction of quinazolines with the ATP binding site
    Arteaga, CL
    Ramsey, TT
    Shawver, LK
    Guyer, CA
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (37) : 23247 - 23254
  • [5] Arteaga CL, 2002, ONCOLOGIST, V7, P31
  • [6] Arteaga CL, 2001, J CLIN ONCOL, V19, p32S
  • [7] Beal S.L., 1992, NONMEM USERS GUIDE 1
  • [8] Bodey B, 1997, ANTICANCER RES, V17, P1319
  • [9] Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy
    Citri, A
    Alroy, I
    Lavi, S
    Rubin, C
    Xu, WP
    Grammatikakis, N
    Patterson, C
    Neckers, L
    Fry, DW
    Yarden, Y
    [J]. EMBO JOURNAL, 2002, 21 (10) : 2407 - 2417
  • [10] PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE
    COCKCROFT, DW
    GAULT, MH
    [J]. NEPHRON, 1976, 16 (01) : 31 - 41